1. First‐in‐man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. (10th January 2013) Authors: Moehrle, Joerg J.; Duparc, Stephan; Siethoff, Christoph; van, Paul L. M.; Craft, J. Carl; Arbe‐Barnes, Sarah; Charman, Susan A.; Gutierrez, Maria; Wittlin, Sergio; Vennerstrom, Jonathan L. Journal: British journal of clinical pharmacology Issue: Volume 75:Number 2(2013:Feb.) Page Start: 535 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects. (17th December 2013) Authors: Saha, Nilanjan; Moehrle, Joerg J.; Zutshi, Anita; Sharma, Pradeep; Kaur, Pawandeep; Iyer, Sunil S. Journal: Journal of clinical pharmacology Issue: Volume 54:Number 4(2014:Apr.) Page Start: 386 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria. (28th June 2021) Authors: Dini, Saber; Zaloumis, Sophie G.; Price, David J.; Gobeau, Nathalie; Kümmel, Anne; Cherkaoui, Mohammed; Moehrle, Joerg J.; McCarthy, James S.; Simpson, Julie A. Journal: Journal of antimicrobial chemotherapy Issue: Volume 76:Number 9(2021) Page Start: 2325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗